alexa In-vitro Tests Suitability in Severe Systemic Reaction due to Several Drugs
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

In-vitro Tests Suitability in Severe Systemic Reaction due to Several Drugs

Dario Antolin-Amerigo1*, Maria Luisa Sanz2, Lucienne Costa-Frossard França3, Teresa Caballero Molina4, Pernila Tirado Zambrano5, Rosario Carrillo Gijón6, Ingrid Rocío Aguayo Leiva7 and Belen de La Hoz Caballer8

1Allergy Division, Hospital Universitario Ramon y Cajal, Madrid, Spain

2Department of Allergology & Clinical Immunology, University Clinic of Navarra, Pamplona, Spain

3Neurology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain

4Allergy Department, Hospital La Paz Health Research Center, Madrid, Spain

5Department of Pathology Service, Hospital Universitario Ramon y Cajal, Madrid, Spain

6Department of Pathology Service, Hospital Universitario Ramon y Cajal, Carretera de Colmenar Km, Madrid, Spain

7Department of Dermatology Service, Hospital Universitario Ramon y Cajal, Madrid, Spain

8Allergy Division, Hospital Universitario Ramon y Cajal, Madrid, Spain

*Corresponding Author:
Dario Antolin-Amerigo
Allergy Division, Hospital Universitario Ramon y Cajal, Madrid, Spain
Tel: 34661715681
Fax: 34-91-3368624
E-mail: [email protected]

Received date: October 27, 2011; Accepted date: March 21, 2012; Published date: March 26, 2012

Citation: Antolin-Amerigo D, Sanz ML, Costa-Frossard França L, Molina TC, Zambrano PT, et al. (2012) in-vitro Tests Suitability in Severe Systemic Reaction due to Several Drugs. J Clin Exp Dermatol Res S2:005. doi: 10.4172/2155-9554.S2-005

Copyright: © 2012 Antolin-Amerigo D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Toxic-Epidermal-Necrolysis might be a severe delayed reaction to drugs, so in-vitro assessment could be suitable. To date there are not validated diagnostic procedures for such cases.
Methods: A 33 year-old female suffering from Multiple-Sclerosis (MS) was receiving Beta1a-Interferon from the last 2.5 months, Deflazacort 1 month and Ibuprofen occasionally. She consulted the emergency department due to confluent dianiform maculae, denudating blisters and subsequent systemic symptoms which led to toxic epidermal necrolysis after skin biopsy result. Cyclosporine, Prednisone, Zinc-Sulfate baths and complete discontinuation of implicated medication achieved total symptom relief. A Basophil Activation Test (BAT) and Lymphocyte-Transformation- Test (LTT) were carried out using Beta1aInterferon, Deflazacort and Ibuprofen at different dilutions for each culprit medication (1/1,1/10,1/102,1/103). Glatiramer-Acetate(GA) hasn´t been reported as TEN/SJS cause, therefore neurology-department considered it as a secure alternative to Beta-1a-Interferon so it was in-vitro assessed likewise.
Results: BAT and LTT results were inconclusive. In vivo tests: Intradermal test to GA at progressive dilutions (1/1,1/10,1/102,1/103,1/104,1/105) resulted negative. Oral Challenge Tests to Acetaminophen-1 mg, Prednisone-30 mg and 1-gram Intravenous Methyl-prednisolone resulted negative.
Conclusion: Up-to-date cutaneous lesions limited to injection sites have been reported following Beta-1a interferon treatment but the former had not been involved in a widespread reaction yet. We present a rare case of TEN due to several drugs in which in-vitro tests have been unhelpful, to manage this condition. Further studies would be helpful to clarify its suitability, mainly in immunomodulating medication.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords